MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine

Vaccine

Volumn 33, Issue 23, 2015, Pages 2629-2636

  Medini, Duccio ^a   Stella, Maria ^a   Wassil, James ^b  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United States)

Author keywords

4CMenB; MATS; Meningitis; Meningococcal Antigen Typing System; Meningococcal B vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; 4CMENB VACCINE; BACTERIAL ANTIGEN;

DRUG SURVEILLANCE PROGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE POLICY; HUMAN; IMMUNOASSAY; LABORATORY TEST; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; CHEMISTRY; HEALTH; ISOLATION AND PURIFICATION; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; NEISSERIA MENINGITIDIS; UTILIZATION; VACCINATION;

ANTIGENS, BACTERIAL; GLOBAL HEALTH; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; VACCINATION;

EID: 84929048475     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.015     Document Type: Review

References (50)

1. Pollard A. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004, 23(12):S274-S279.
2. Centers for Disease Control and Prevention Active bacterial core surveillance report: emerging infections program network; Neisseria meningitidis 2008, http://www.cdc.gov/abcs/reports-findings/survreports/mening08.html [accessed 20.02.14].
3. European Centre for Disease Prevention and Control Surveillance of invasive bacterial diseases 2011, http://www.ecdc.europa.eu/en/publications/Publications/invasive-bacterial-diseases-surveillance-2011.pdf [accessed 20.02.14].
4. Zollinger W.D., Poolman J.T., Maiden M.C. Meningococcal serogroup B vaccines: will they live up to expectations?. Expert Rev Vaccines 2011, 10(5):559-561.
5. Budroni S., Siena E., Dunning Hotopp J.C., Seib K.L., Serruto D., Nofroni C., et al. Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci USA 2011, 108:4494-4499.
6. Brehony C., Jolley K.A., Maiden M.C. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 2007, 31:15-26.
7. Holst J., Oster P., Arnold R., Tatley M.V., Næss L.M., Aaberge I.S., et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccines Immunother 2013, 9:1241-1253.
8. Bai X., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2001, 11:969-985.
9. Caron F., du Châtelet I.P., Leroy J.P., Ruckly C., Blanchard M., Bohic N., et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 2011, 11:455-463.
10. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987, 138:4402-4407.
11. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
12. Su E.L., Snape M.D. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines 2011, 10:575-588.
13. Martin D.R., Ruijne N., McCallum L., O'Hallahan J., Oster P. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13:486-491.
14. Martin S.L., Borrow R., van der Ley P., Dawson M., Fox A.J., Cartwright K.A. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000, 18:2476-2481.
15. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines: an unfinished story. Lancet Infect Dis 2010, 10:112-124.
16. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362:1511-1520.
17. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(29):10834-10839.
18. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Aricò B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
19. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000, 3(5):445-450.
20. ®, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe 2012, Available at http://www.novartis.com/newsroom/media-releases/en/2012/1658747.shtml [accessed 21.08.14].
21. FDA News Release FDA approves a second vaccine to prevent serogroup B meningococcal disease 2015, Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431370.htm.
22. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
23. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969, 129:1327-1348.
24. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969, 129:1367-1384.
25. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 1969, 129:1385-1395.
26. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998, 95:3140-3145.
27. Sacchi C.T., Lemos A.P.S., Brandt M.E., Whitney A.M., Melles C.E.A., Solari C.A., et al. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Vaccine Immunol 1998, 5(6):845-855.
28. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107:19490-19495.
29. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381(9869):825-835.
30. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307(6):573-582.
31. Santolaya M.E., O'Ryan M., Valenzuela M.T., Prado V., Vergara R.F., Muñoz A., et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccine Immunother 2013, 9(11). Epub 2013 June 28.
32. Plikaytis B.D., Stella M., Boccadifuoco G., DeTora L.M., Agnusdei M., Santini L., et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS: a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012, 19(10):1609-1617.
33. Tozer S.J., Whiley D.M., Smith H.V., Rockett R., Jennison A., Doyle C., et al. The use of the Meningococcal Antigen Typing System (MATS) to assess Australian epidemiology and meningococcal strain coverage with multicomponent serogroup B vaccine. Poster presented at 27th ICP 2013.
34. Lemos A., Gorla M., Brandileone M., Orlandi L., Rigat F., Boccadifuoco G., et al. MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitidis B (MenB) Brazilian invasive strains. Poster presented at 18th international pathogenic Neisseria conference (IPNC) meeting 2012, Poster P272.
35. Bettinger J.A., Scheifele D.W., Halperin S.A., Vaudry W., Findlow J., Borrow R., et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013, 32(1):124-130.
36. Křížová P., Musílek M., Vacková Z., Kozáková J., Claus H., Vogel U., et al. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol 2014, 63(2):103-106.
37. Vogel U., Taha M.K., Vazquez J.A., Findlow J., Claus H., Stefanelli P., et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13(5):416-425.
38. Tzanakaki G., Hong E., Kesanopoulos K., Xirogianni A., Bambini S., Orlandi L., et al. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol 2014, 14:111.
39. Kim E., Paulos S., Carlone G., Plikaytis B., Cohn A., Messonnier N., et al. Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States. Poster presented at 18th IPNC 2012, Poster P270.
40. ®) on non-serogroup B disease burden in Brazil. Poster presented at ESPID 2014.
41. Centers for Disease Control and Prevention Princeton University meningococcal disease outbreak 2014, Available at: http://www.cdc.gov/meningococcal/outbreaks/princeton.html [last updated 18.03.14].
42. Centers for Disease Control and Prevention University of California, Santa Barbara meningococcal disease outbreak 2014, Available at: http://www.cdc.gov/meningococcal/outbreaks/ucsb.html [last updated 18.03.14].
43. Centers for Disease Control and Prevention. Outbreaks of Serogroup B Meningococcal Disease on University Campuses 2013. Prepared by Patel, Manish. Meningitis and Vaccine Preventable Diseases Branch. Available at. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-02/04-mening-patel.pdf.
44. Hong E., Giuliani M.M., Deghmane A.E., Comanducci M., Brunelli B., Dull P., et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?. Vaccine 2013, 31(7):1113-1116.
45. Sanders H., Feavers I.M. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vaccines 2011, 10(3):323-334.
46. Vu D.M., Wong T.T., Granoff D.M. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 2011, 29(10):1968-1973.
47. Fagnocchi L., Biolchi A., Ferlicca F., Boccadifuoco G., Brunelli B., Brier S., et al. Transcriptional regulation of the NadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun 2013, 81(2):560-569.
48. Delany I., Antunes A., Haag A., Boccadifuoco G., Biolchi A., Brunelli B. Poster presented at 18th international pathogenic Neisseria conference (IPNC) meeting 2012, Poster 013.
49. Frosi G., Biolchi A., Lo Sapio M., Rigat F., Gilchrist S., Lucidarme J., et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013, 31(43):4968-4974.
50. Snape M.D., Medini D., Halperin S.A., DeTora L., Drori J., Moxon E.R. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30(Suppl. 2):B67-B72.